Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of S241656 in KRAS, BRAF, and other RAS/MAPK mutation-positive solid tumors
2025-523474-16-00Phase 2Authorised
- Sponsor
- Servier
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label trial of bdtx-4933 in solid tumor with RAS/MAPK pathway alteration, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma (PDAC) and 2 more (12 arms), sponsored by Servier. Primary endpoints: Dose-limiting toxicities, Adverse events and serious adverse events and 1 more. Planned start Jun 2026; status: authorised.
02
Drugs
bdtx-4933
03
Conditions
solid tumor with RAS/MAPK pathway alterationnon-small cell lung cancer (NSCLC)pancreatic adenocarcinoma (PDAC)colorectal cancer (CRC)biliary cancer
Beyond the preview
Go deeper on 2025-523474-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523474-16-00.